Introduction {#sec1-0300060517720099}
============

Disseminated intravascular coagulation (DIC) is a dynamic pathologic process triggered by abnormal activation of the blood coagulation pathway.^[@bibr1-0300060517720099]^ DIC reportedly develops in 10% to 15% of patients with cancer, and its mechanism is largely explained by release of procoagulants (e.g., tissue factor) from cancer cells with resultant derangement of the coagulation system.^[@bibr2-0300060517720099]^ Most patients with cancer exhibit a chronic or low-grade phenotype of DIC in which the triggering factor is slowly released and compensated for. However, acute DIC may develop when blood is exposed to large amounts of procoagulants in a short time, resulting in severe bleeding, thromboembolic events, or death.^[@bibr3-0300060517720099]^ This report serves as a reference in treating *EGFR* mutation-positive lung cancer in patients with DIC.

Case report {#sec2-0300060517720099}
===========

An 82-year-old Korean man (nonsmoker) was diagnosed with basal cell carcinoma (BCC) on his left flank and lung adenocarcinoma that had metastasized to multiple lymph nodes, the pleura, bone, liver, and adrenal gland ([Figure 1](#fig1-0300060517720099){ref-type="fig"}). He underwent surgical excision of the BCC under local anesthesia, but the bleeding did not stop even after compression of the surgical site. The patient had no history of bleeding, thromboembolic disease, or treatment with anticoagulants. He subsequently developed fatigue, jaundice, and purpura on his anterior chest wall. His coagulation and fibrinolytic systems were immediately analyzed to identify the cause of the bleeding ([Figure 2](#fig2-0300060517720099){ref-type="fig"}). Under a diagnosis of acute DIC, he received a total of 12 units of fresh frozen plasma over 3 consecutive days. However, the bleeding was not controlled, and the abnormalities in his coagulation and fibrinolytic systems were not corrected. Additionally, his Eastern Cooperative Oncology Group performance status worsened, increasing from a score of 1 to 3. Four days after BCC excision, the patient was found to have an L858R mutation in his epidermal growth factor receptor (EGFR) gene, and erlotinib was thus immediately administered. Two days later, his laboratory test results began to dramatically improve. Four days later, the clinical features of DIC disappeared and all laboratory abnormalities were corrected. One month later, a nearly complete response to the erlotinib treatment was noted. Figure 1.\[18F\]Fluorodeoxyglucose positron emission tomography findings. (a) At the time of diagnosis. (b) After administration of erlotinib. Figure 2.Changes in coagulation and fibrinolysis parameters (a) Fibrinogen level, platelet count, and prothrombin time (PT). (b) Activated partial thromboplastin time (aPTT), total bilirubin level, and D-dimer level.

Because this report was appropriately anonymized, approval from the institutional review board was waived. Written informed consent was obtained from the patient for publication of this report.

Discussion {#sec3-0300060517720099}
==========

To our knowledge, no reports to date have described a patient with lung cancer complicated by acute DIC that was successfully treated with erlotinib. In the present case, the surgical excision of the coincident BCC was thought to have triggered the DIC by accelerating the consumption of coagulation factors. Because the cornerstone of treatment of DIC is effective management of lung cancer, molecular-targeted agents in the postgenomic era can be used to successfully treat patients with driver mutations.

Activation mutations of the *EGFR* gene are found in 10% to 26% of patients with non-small cell lung cancer (NSCLC) and tend to have a favorable response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib.^[@bibr4-0300060517720099],[@bibr5-0300060517720099]^ In some landmark studies,^[@bibr4-0300060517720099],[@bibr5-0300060517720099]^ progression-free survival was significantly better in patients with NSCLC treated with erlotinib as a first-line therapy than in patients who underwent standard chemotherapy. However, overall survival was similar between the two groups by the crossover effect, suggesting that either an EGFR-TKI or standard chemotherapy is a reasonable candidate as a first-line regimen for such patients. EGFR-TKIs are reportedly more beneficial as a first-line regimen in patients with a poor performance status.^[@bibr5-0300060517720099]^ Successful treatment with anaplastic lymphoma kinase-TKIs for acute DIC has been reported in patients with anaplastic lymphoma kinase-positive NSCLC.^[@bibr6-0300060517720099],[@bibr7-0300060517720099]^ However, this has rarely been reported in patients undergoing systemic chemotherapy^[@bibr8-0300060517720099]^ because chemotherapeutic agents including cisplatin are known to cause DIC through endothelial damage, while EGFR-TKIs do not cause such damage.^[@bibr9-0300060517720099],[@bibr10-0300060517720099]^

The present case report provides more evidence for the consideration of EGFR-TKIs as a first-line treatment in patients with an activating *EGFR* mutation. Physicians should be aware that acute DIC can develop even after minor surgery. This report provides physicians with a reference for treating *EGFR* mutation-positive lung cancer in patients with DIC.
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